The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Wednesday, 23 February 2022.
For more information, download the attached PDF.
Download this document
